Inspira Technologies Secures $22.5 Million Purchase Order, Launches Full Revenue Execution Phase
July 2, 2025
Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) ("Inspira," “Inspira Technologies,” or the "Company"), a pioneer in innovative life-support and diagnostic technologies, today announced it has secured a binding $22.5 million purchase order for its FDA-cleared ART100 system, representing a major commercial inflection point for the Company. The order was placed by a privately held company headquartered outside the United States, in a global strategic hub, with an established track record and active commercial ties to both government entities and institutional healthcare customers.
Under the terms of the binding purchase order, full payment of $22.5 million is to be made during 2025. Inspira and the purchasing organization have initiated onboarding, logistics planning, and deployment scheduling, with immediate implementation.
This purchase order is a significant commercial milestone for Inspira, marking a clear transition into full-scale revenue generation. Inspira estimates that this purchase order represents only a small portion of the total addressable market the Company is currently targeting globally.
"We view this order as a signal of the broad activation of Inspira’s commercial model,” said Dagi Ben-Noon, CEO of Inspira Technologies. “It is a vote of confidence in our technology, confirms market demand, and signals to the market that we are executing in real-world settings. The clinical use of the ART100 in top U.S. medical centers opened the door to this agreement, and it lays the foundation for the next wave of global deployments already underway.”
Inspira is currently in advanced negotiations with additional healthcare companies and governmental institutions across multiple regions. These discussions are progressing toward commercial agreements that are expected to be announced in the near term, further supporting the Company’s commercial expansion strategy.
This announcement follows a series of major company milestones, including successful clinical integration in Tier-1 hospitals, and manufacturing expansion. Inspira is actively scaling its commercial infrastructure to support accelerated pipeline expansion and recurring deployments on a global scale.
About Inspira Technologies Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s U.S. Food and Drug Administration -cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500 — a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. The Company’s recent internal shifts may reflect broader alignment with long-term industry trends, including consolidation, cross-sector collaboration, and potential strategic partnerships. For more information, visit: https://inspira-technologies.com
Market Data 
Markets 
AI
